SCHEMBL449653

SCHEMBL449653

O=C(NCCc1ccc(OCCCCCc2ccccc2)cc1)c1cc(O)cc(O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
NPC1 O15118 4/20 0.63
RAB9A P51151 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.60
MAPT P10636 3/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
S1PR1 P21453 4/20 0.56
S1PR3 Q99500 2/20 0.56
S1PR5 Q9H228 1/20 0.56
FFAR1 O14842 1/20 0.54
TAAR1 Q96RJ0 1/20 0.52
PLA2G4B P0C869 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4657049 0.89 MEN1 (0.65) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL453480 0.89 MEN1 (0.61) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4658285 0.86 MEN1 (0.64) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL437736 0.84 NPC1 (0.64) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4658990 0.84 NPC1 (0.64) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4657235 0.83 MEN1 (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4658105 0.82 KDM5B (0.63) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4657655 0.82 KMT2A (0.59) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4658045 0.81 KDM5B (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4656460 0.81 MEN1 (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653305-B2 Compound having S1P receptor binding potency and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-02-18 US claimed
US-8653305-B2 Compound having S1P receptor binding potency and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-02-18 US disclosed
US-20120064060-A1 COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 US disclosed
US-8039674-B2 Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents ONO PHARMACEUTICAL CO., LTD. (JP) 2011-10-18 US disclosed
US-20080207584-A1 Compound Having S1P Receptor Binding Potency and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-28 US disclosed
EP-1760071-A1 COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064060-A1 COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF S1PR1, S1PR3, EDNRA MEN1 1245/4885KMT2A 2641/4885NPC1 796/4885
US-20080207584-A1 Compound Having S1P Receptor Binding Potency and Use Thereof S1PR1, EDNRA, S1PR3 MEN1 1153/4885KMT2A 2410/4885NPC1 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.